All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @loracroftcheck on TikTok · 24s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @loracroftcheck's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thanks for watching!

TikTok creator's GLP-1 blood pressure claims fact-checked

Lora Croftcheck

TikTok creator

221.8K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and affecting appetite regulation in the brain. Clinical trials show 15-22% average weight loss, with secondary benefits including blood pressure reduction of 6-10 mmHg.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok creator's GLP-1 blood pressure claims fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TikTok creator's GLP-1 blood pressure claims fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok creator's GLP-1 blood pressure claims fact-checked" from Lora Croftcheck. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and affecting appetite regulation in the brain.

The reason this review is not generic is the source wording and the canonical claim label "glp1 21 weeks on my glp 1 journey with mochi and i couldn t be h." In this clip, the useful excerpt is: "Thanks for watching!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 demonstrated 15-22.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and affecting appetite regulation in the brain.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and affecting appetite regulation in the brain. Clinical trials show 15-22% average weight loss, with secondary benefits including blood pressure reduction of 6-10 mmHg.
  • STEP 1 trial showed semaglutide 2.4mg reduced systolic blood pressure by 6.2 mmHg at 68 weeks
  • SURMOUNT-1 demonstrated 15-22.5% weight loss with tirzepatide, enough to move many patients to healthy BMI

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • STEP 1 trial showed semaglutide 2.4mg reduced systolic blood pressure by 6.2 mmHg at 68 weeks
  • SURMOUNT-1 demonstrated 15-22.5% weight loss with tirzepatide, enough to move many patients to healthy BMI
  • Up to 44% of patients experience nausea on semaglutide according to clinical trial data
  • About 12% discontinue GLP-1 medications due to gastrointestinal side effects
  • Stopping blood pressure medication requires medical supervision and gradual tapering
  • 32% of STEP 1 participants achieved less than 5% weight loss with semaglutide
  • Individual results vary significantly despite average weight loss of 15-20% in trials

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@loracroftcheck says she's been off blood pressure medications and moved from an unhealthy to healthy BMI after 21 weeks on a GLP-1 medication through Mochi Health. She's promoting eligibility for the telehealth service while sharing her personal transformation story.

The creator doesn't specify which GLP-1 medication she's taking, though Mochi Health typically prescribes semaglutide or tirzepatide. Her claims focus on two major health improvements: eliminating blood pressure medication and achieving a healthy BMI range.

Do GLP-1 medications actually improve blood pressure?

Yes, and the data is solid. The STEP 1 trial (Wilding et al., NEJM, 2021) found semaglutide 2.4mg reduced systolic blood pressure by 6.2 mmHg compared to placebo at 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed tirzepatide reduced systolic BP by 7.4-10.6 mmHg depending on dose.

These aren't small changes. A 5 mmHg reduction in systolic blood pressure typically reduces cardiovascular risk by about 10%. Weight loss of 15-20% often allows patients to reduce or eliminate blood pressure medications under medical supervision.

The timeline makes sense too. Most patients see meaningful blood pressure improvements within 12-16 weeks of starting GLP-1 therapy as weight loss progresses.

What about the BMI claims?

Moving from an unhealthy to healthy BMI in 21 weeks is achievable with GLP-1 medications, depending on starting weight. The STEP 1 trial showed 14.9% average weight loss at 68 weeks with semaglutide, while SURMOUNT-1 demonstrated 15-22.5% weight loss with tirzepatide.

Someone starting with a BMI of 32 (class 1 obesity) would need about 15% weight loss to reach a BMI under 25. That's absolutely possible in 21 weeks with these medications.

However, the creator doesn't share specific numbers. Without knowing her starting BMI or total weight lost, we can't verify her exact claims.

What's missing from this promotion?

The video glosses over side effects, which is misleading. Up to 44% of patients experience nausea on semaglutide 2.4mg, and 12% discontinue treatment due to gastrointestinal issues according to STEP 1 data.

She also doesn't mention that stopping blood pressure medication requires medical supervision. You can't just quit based on feeling better. Blood pressure needs monitoring and gradual medication tapering.

The promotional aspect is concerning too. While she discloses her connection to Mochi Health, the video reads more like an advertisement than balanced health information.

What should you actually know?

GLP-1 medications can genuinely improve blood pressure and BMI, but individual results vary widely. Not everyone achieves healthy BMI ranges, and not everyone can discontinue blood pressure medications.

The STEP 1 trial showed 32% of patients achieved less than 5% weight loss with semaglutide. About 15% discontinued due to side effects. These medications work well for many people but aren't magic bullets.

If you're considering GLP-1 therapy, discuss realistic expectations with your doctor. Blood pressure medication changes require medical oversight, and weight loss timelines vary significantly between individuals.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Lora Croftcheck · TikTok creator

221.8K views on this video

21 weeks on my glp-1 journey with Mochi, and I couldn’t be happier with my results. I am officially off my blood pressure medications, and my BMI is now in the healthy range. Want to see if you are el

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial showed semaglutide 2.4mg reduced systolic blood pressure?

STEP 1 trial showed semaglutide 2.4mg reduced systolic blood pressure by 6.2 mmHg at 68 weeks

What does the video say about surmount-1 demonstrated 15-22.5% weight loss with tirzepatide, enough to move?

SURMOUNT-1 demonstrated 15-22.5% weight loss with tirzepatide, enough to move many patients to healthy BMI

What does the video say about up to 44% of patients experience nausea on semaglutide according?

Up to 44% of patients experience nausea on semaglutide according to clinical trial data

What does the video say about about 12% discontinue glp-1 medications due to gastrointestinal side effects?

About 12% discontinue GLP-1 medications due to gastrointestinal side effects

What does the video say about stopping blood pressure medication requires medical supervision?

Stopping blood pressure medication requires medical supervision and gradual tapering

What does the video say about 32% of step 1 participants achieved less than 5% weight?

32% of STEP 1 participants achieved less than 5% weight loss with semaglutide

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Lora Croftcheck, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.